Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDXG 
MiMedx Group Inc (MDXG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: MDXG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.2
1 Year Target Price $12.2
| 5 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 21.43% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.03B USD | Price to earnings Ratio 33.19 | 1Y Target Price 12.2 |
Price to earnings Ratio 33.19 | 1Y Target Price 12.2 | ||
Volume (30-day avg) 5 | Beta 1.74 | 52 Weeks Range 5.47 - 10.14 | Updated Date 09/16/2025 |
52 Weeks Range 5.47 - 10.14 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.84% | Operating Margin (TTM) 12.55% |
Management Effectiveness
Return on Assets (TTM) 10.37% | Return on Equity (TTM) 16.61% |
Valuation
Trailing PE 33.19 | Forward PE 19.53 | Enterprise Value 930869129 | Price to Sales(TTM) 2.83 |
Enterprise Value 930869129 | Price to Sales(TTM) 2.83 | ||
Enterprise Value to Revenue 2.55 | Enterprise Value to EBITDA 17.57 | Shares Outstanding 147959008 | Shares Floating 108772365 |
Shares Outstanding 147959008 | Shares Floating 108772365 | ||
Percent Insiders 1.7 | Percent Institutions 71.51 |
Upturn AI SWOT
MiMedx Group Inc
Company Overview
History and Background
MiMedx Group Inc. was founded in 2008. It focuses on developing and marketing regenerative biomaterials derived from human placental tissue. The company has faced legal and accounting challenges, undergoing significant restructuring and management changes.
Core Business Areas
- Wound Care: Development and distribution of advanced wound care products derived from placental tissue, used to treat chronic and acute wounds.
- Surgical: Development and distribution of surgical products that leverage placental tissue for various surgical applications, including tissue repair and regeneration.
- Sports Medicine: Development and distribution of products used in sports medicine to address musculoskeletal injuries.
Leadership and Structure
The company has a board of directors and an executive leadership team. Key roles include the Chief Executive Officer, Chief Financial Officer, and Chief Medical Officer. The structure is organized around functional areas such as R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- EpiFix: A dehydrated human amnion/chorion membrane (dHACM) allograft used for wound healing. Competitors include Integra LifeSciences and Organogenesis. Limited public data on market share due to company specifics, but estimated to be a major revenue driver prior to its regulatory challenges. Revenue figures vary.
- AmnioFix: Another dHACM allograft, typically used in surgical applications. Competitors include Integra LifeSciences. Market share data not readily available.
Market Dynamics
Industry Overview
The regenerative medicine market is experiencing substantial growth, driven by an aging population and increasing demand for advanced wound care and surgical solutions. Key trends include technological advancements in biomaterials and increasing regulatory scrutiny.
Positioning
MiMedx positions itself as a leader in placental-derived biomaterials for wound care and surgical applications. Its competitive advantages include its proprietary technology and established distribution network, though past regulatory hurdles significantly impacted their positioning.
Total Addressable Market (TAM)
The global regenerative medicine market is estimated to be in the tens of billions USD, with segments relevant to MiMedx including wound care and orthopedics. MiMedx's ability to capture TAM is impacted by its past legal challenges and market competition.
Upturn SWOT Analysis
Strengths
- Proprietary placental tissue processing technology
- Established product portfolio (EpiFix, AmnioFix)
- Potential for innovation in regenerative medicine
- Experienced scientific team
Weaknesses
- Past legal and accounting issues
- Regulatory hurdles
- Reliance on placental-derived products
- Limited financial transparency
Opportunities
- Expanding applications of placental-derived biomaterials
- Partnerships with hospitals and clinics
- Geographic expansion into emerging markets
- Development of new regenerative medicine products
Threats
- Competition from established medical device companies
- Regulatory changes affecting placental-derived products
- Potential for product liability claims
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- ICEL
- ALVR
- Integra LifeSciences (IART)
Competitive Landscape
MiMedx faces competition from larger, more established medical device companies. Its key advantages lie in its proprietary technology, but it needs to overcome past regulatory issues to regain a strong competitive position.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been erratic due to the company's past challenges.
Future Projections: Analyst projections vary, dependent on the company's ability to regain market trust and navigate regulatory pathways.
Recent Initiatives: Recent initiatives include a focus on compliance, regulatory approvals, and new product development.
Summary
MiMedx is navigating a challenging recovery phase after past legal and accounting issues. Their proprietary technology and established product lines offer potential for growth, but regulatory hurdles and intense competition remain significant concerns. The company is focused on rebuilding trust and regaining market share. Success hinges on effective compliance and successful new product launches.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MiMedx Group Inc
Exchange NASDAQ | Headquaters Marietta, GA, United States | ||
IPO Launch date 2007-08-22 | CEO & Director Mr. Joseph H. Capper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 837 | Website https://www.mimedx.com |
Full time employees 837 | Website https://www.mimedx.com | ||
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.